Atlas Trials

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Clinical trial NCT04336943 · TERMINATED

Trial details

NCT number
NCT04336943
Sponsor
University of Washington
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Biochemically Recurrent Prostate CarcinomaProstate Adenocarcinoma
Start date
2021-04-13
Primary completion
2024-06-20
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.